Quadria Capital on Monday said it has invested $102 million in India's largest dialysis chain NephroPlus, picking up a minority stake in the company as the Asia-focussed private equity firm keeps investing in regional healthcare providers. 'The transaction will support NephroPlus in serving the growing demand for high quality, affordable dialysis services across India and other markets in Asia,' Singapore-headquartered Quadria said.

Quadria Capital周一表示，它已向印度最大的透析连锁企业NephroPlus投资1.02亿美元，收购了该公司的少数股权，因为这家专注于亚洲的私人股本公司继续投资于地区医疗保健提供商总部位于新加坡的Quadria表示，这笔交易将支持NephroPlus满足印度和亚洲其他市场对高质量、价格合理的透析服务日益增长的需求。

The PE firm expects demand for dialysis, a blood purifying treatment for kidney disorders, to grow over the next five in the markets it is targeting to grow. The Economic Times on Friday reported that the fresh investment values NephroPlus at more than $239.6 million. NephroPlus operates about 450 dialysis centres and operates in three main countries namely India, the Philippines and Uzbekistan.

这家私人股本公司预计，透析（一种治疗肾脏疾病的血液净化疗法）的市场需求将在未来五年增长。《经济时报》周五报道称，NephroPlus的新投资价值超过2.396亿美元。NephroPlus在印度、菲律宾和乌兹别克斯坦三个主要国家运营着约450家透析中心。

Quadria, which manages total assets of over $3.4 billion, has in the past invested in other Indian healthcare providers including eye-care chain Maxivision and oncology network HCG.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

Quadria管理着超过34亿美元的总资产，过去曾投资于其他印度医疗保健提供商，包括眼科保健连锁公司Maxivision和肿瘤网络HCG。（您现在可以订阅我们的经济时报WhatsApp频道）（您现在可以订阅我们的经济时报WhatsApp频道）。